Showing results (571-580 of 2,330) with videos related to
Sort By:
Pageof 233
Clinical Drug Investigation|September 8, 2010
Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre studyMark S Wallace, Gordon Irving, Verne E CowlesClinical Drug Investigation|September 8, 2010
Treatment of advanced Parkinson's disease in the United States: a cost-utility modelHuybert Groenendaal, Marcy L Tarrants, Christophe ArmandClinical Drug Investigation|October 12, 2010
Effects of two administration schemes of intramuscular clodronic acid on bone mineral density: a randomized, open-label, parallel-group studyBruno FredianiClinical Drug Investigation|March 4, 2011
Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label studyElena Di Nasso, Alberto Chiesa, Alessandro Serretti, et al.Clinical Drug Investigation|August 18, 2010
Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysisChristopher Carswell, Amanda Wheeler, Jane Vanderpyl, et al.Clinical Drug Investigation|July 15, 2010
Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trialsMichael Schiff, Andre Beaulieu, David L Scott, et al.Clinical Drug Investigation|July 15, 2010
Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartanPedro Marques da SilvaClinical Drug Investigation|July 31, 2010
Idiopathic breakthrough pain: a new hypothesisAlessandro Fabrizio SabatoClinical Drug Investigation|June 10, 2010
Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group studyRené AalbersClinical Drug Investigation|June 10, 2010
Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled studySteven G ChrysantPageof 233